glutathione and ototoxicity Pharmacological activation of GPX4 by selenomethionine attenuates cisplatin-induced hearing loss Evaluating protective and therapeutic effects
Description
The technical requirements, financial investment, and regulatory complexity make this process difficult to complete within a short timeframe
Safety Profile: What Clinical Trials Actually Documented Across six clinical trials involving approximately 900 participants, AOD-9604 produced no treatment-related serious adverse events, no immunogenic response, no IGF-1 elevation, and no adverse cardiovascular or metabolic signals
Then measure at regular intervals (every four to eight weeks) under identical conditions
Genentech, Inc., Cooperative Study Group
